Detalhe da pesquisa
1.
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Haematologica
; 107(7): 1599-1607, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551507
2.
Erratum to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Haematologica
; 109(4): 3010, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38562076
3.
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
Lancet Oncol
; 16(9): 1025-1036, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26234174
4.
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Haematologica
; 100(2): 231-7, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25381131
5.
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
Blood
; 120(13): 2573-80, 2012 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-22896000
6.
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.
Haematologica
; 103(11): e514-e518, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29794146
7.
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.
Blood Adv
; 7(19): 5835-5842, 2023 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552106
8.
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.
Blood Adv
; 4(22): 5825-5835, 2020 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33232476
9.
Induction of complete remission using single agent clofarabine in a patient with primary refractory acute myeloblaste leukemia.
Leuk Lymphoma
; 44(12): 2135-6, 2003 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-14959859